LYMPHOCYTES EXPRESSING HETEROLOGOUS TARGETING CONSTRUCTS

The present invention provides engineered lymphocytes (e.g., ?d T cells, NK cells, NK-like T cells, engineered innate lymphoid cells, or MAIT cells) comprising a heterologous targeting construct lacking an intracellular signaling domain capable of activating the lymphocyte on which the construct is...

Full description

Saved in:
Bibliographic Details
Main Authors NUSSBAUMER, Oliver, PIZZITOLA, Irene, KOVACS, Istvan, MEHTA, Raj
Format Patent
LanguageEnglish
Published 07.06.2021
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention provides engineered lymphocytes (e.g., ?d T cells, NK cells, NK-like T cells, engineered innate lymphoid cells, or MAIT cells) comprising a heterologous targeting construct lacking an intracellular signaling domain capable of activating the lymphocyte on which the construct is expressed. Further provided are compositions of engineered lymphocytes (e.g., ?d T cells) and methods of using the engineered lymphocytes (e.g., ?d T cells, e.g., a part of an adoptive T cell therapy).
Bibliography:Application Number: PH20201551538